Name: Latest research reports of Zydus Lifesciences Ltd. authored by Phillip Capital and published by - Trendlyne research reports.
Item: Zydus Lifesciences Ltd.
Rating: 3
Author: Phillip Capital

Zydus Lifesciences Ltd.

NSE: ZYDUSLIFE | BSE: 532321 | ISIN: INE010B01027 | Industry: Pharmaceuticals
| Mid-range Performer

975.0000 -44.25 (-4.34%)

NSE Sep 26, 2025 15:31 PM

Volume: 2.6M

High volume today

Zydus Lifesciences Ltd.

08 Feb 2016

975.00

-4.34%

Cadila 8Feb2016

Neutral: Zydus Lifesciences Ltd.

Target

Phillip Capital

9 CDH management is optimistic about the quick resolution of Warning Letter on its Moraiyaplant.ItexpectcontinuedUSgrowthmomentumledbynewlaunchesfromits recentlyUSFDAapprovedalternateplantsatBaddiandAhmadabadSEZ....

Zydus Lifesciences L.. has an average target of 1045.33 from 6 brokers.